Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Pharma Industry News MoonLake Immunotherapeutics says FDA supports existing clinical data for sonelokimab, announces investor day amid strong market reaction Find out how MoonLake Immunotherapeutics gained FDA support for its sonelokimab data and why investors are watching its 2026 regulatory path closely. bySoujanya RaviJanuary 8, 2026